Study of drug utilization review on patients diagnosed with “Covid-19” and hospitalized in Mongolia-Japan Hospital of Mongolian National University of Medical Sciences

Abstract

Background: At the end of 2019, a new coronavirus infection broke out in Wuhan, Hubei Province, China, and on February 11, 2020, the World Health Organization (WHO) ofÏcially named the new coronavirus infection “Kovid-19” and “New Coronavirus Disease 2019”. The International Committee of Virus Taxonomy also named the pathogen SARSCov-2. Every country is making a huge amount of effort to study more about the novel Coronavirus “Covid-19” and its epidemiology and looking for a proficient way to improve its prevention, diagnosis and treatment. As for Mongolia-Japan Hospital, an associate of Mongolian National University of Medical Sciences, we have been using “Covid-19” medications prescribed under the temporary guideline approved upon the Order No. А/254, А/467 and А/549 by the Minister of Health of Mongolia dated in 2021 and guidelines from the other nations and international institutes such as WHO, USA and Europe. Different variety of symptoms and severity level in patients require us to be more accurate and consistent on pharmaceutical provisions and management which also became a main background to conduct this study. Materials and Methods: Retrospective method has been used in this review integrating data from the Unicus program and disease history and medication used on a total of 1401 “Covid-19” patients hospitalized in the Mongolia-Japan Teaching Hospital from the 18th of April to the 31st of August, 2021. Results: “Covid-19” The cost of antiviral and antimicrobial drugs is the highest in the total cost of drugs used to treat the disease. Of the drugs used, 57.58% were used for antidepressants, 33.38% for symptomatic treatment, and 9.04% for comorbidities. These include anticoagulants (anticoagulants and antiplatelet agents alone or in combination), cardiovascular drugs (antihypertensives, diuretics), glucocorticoids (dexamethasone), gastrointestinal drugs (famotidine), and expectorants. acetylcysteine), antihistamines and anti-inflammatory drugs (montelukast), antidepressants, and vitamins (vitamins C and D). Therefore, it is necessary to focus on improving resource management and improving drug safety based on the use of drugs by inpatients “Covid-19”. The medication reserve in the hospital should be accumulated properly and medication safety should be improved through this kind of practical review of medication input at the hospitals.